Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Novo Nordisk's blockbuster drug is now a kidney disease fighter, threatening dialysis giants and reshaping the ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

The U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Novo Nordisk’s (NVO) Ozempic medication to ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF ...